Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving FOLFOXIRI/Bevacizumab for Metastatic Colorectal Cancer (mCRC):
Status:
Recruiting
Trial end date:
2024-11-30
Target enrollment:
Participant gender:
Summary
This is a randomized, double-blind, placebo-controlled, global, multicenter, Phase 3 trial
evaluating the impact of trilaciclib on myelopreservation and anti-tumor efficacy when
administered prior to FOLFOXIRI/bevacizumab in patients with pMMR/MSS mCRC who have not
received systemic therapy for metastatic disease.